GERN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.0%, SMA50 12.29%, SMA200 21.14%). The stock’s 14-day RSI is 51.44 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.91% below its high and over 58.65% above its low. Average 10-day trading volume of 8.34 million shares is below the 3-month average of 10.82 million, indicating normal recent market interest.

Geron Corporation generated EPS of -$0.13 over the past year. Five-year average earnings growth is 14.31%. The latest quarter delivered EPS of -$0.02. The next quarter is forecast at -$0.02. Next year's EPS is expected at -$4.37. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 207.69% upside. The low target suggests 207.69% downside. The mean target is $4.00. This offers 207.69% upside. Geron Corporation earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by 125.23%. The prior quarter beat by -66.67%. Over the last six quarters, Apple has recorded several small beats. These include -25.0% in May 07, 2025.

Geron Corporation has 642.47 million shares outstanding. The public float is 556.32 million shares, elevated short interest at 12.56% of float. This equals 80.60 million shares. The short ratio is 7.7 days. Institutional investors hold 79.98% of the float. Insiders own 0.08%. GREENWOOD DAVID holds 754.03 thousand shares, LEBKOWSKI JANE has 568.15 thousand shares and Kelsey Stephen Michael has 473.12 thousand shares.

Geron Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Geron Corporation (NASDAQ:GERN) closed at $1.30 USD, losing -$0.02 (-1.52%) from the previous close of $1.32. The stock is currently mid-range between its 52-week high and low $1.04 and $2.01. With a market capitalization of about $833.98 million, Geron Corporation is classified as a small-cap and shows lower-than-market volatility (beta ~0.60). Key stats such as the average daily volume over the past year has been around 11.27 million shares, trading with heavier-than-usual volume. Headquartered in Foster City, CA, Geron Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Harout Semerjian, the company employs approximately 258 people and listed since July 31, 1996. Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers.

Geron Corporation trades at a P/E ratio of -13.04, slightly below the S&P 500 average, with a price-to-sales ratio of 4.08 and a price-to-book ratio of 3.99 trading at moderately above to book value. The P/FCF stands at -7.26, also below market averages.

Geron Corporation (NASDAQ:GERN) shares are flat -1.52% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Geron Corporation trading at a premium to the broader market with a P/E of -13.04. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.90, suggesting 276.92% upside. Our AI forecast model points to short-term weakness (-10.0% over two weeks), a medium-term fall (-36.92% over three months), and a longer-term gain (541.54% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Geron Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.0%, with price expected at $1.17 by October 02, 2026, within a range of $1.09 to $1.25 3-Month Outlook: Projected fall of -36.92%, reaching $0.82 by December 17, 2026, with a range of $0.67 to $0.91. 1-Year Outlook: Projected gain of 541.54%, with price at $8.34 by September 17, 2027, within a range of $1.57 to $12.06.